C-RAD AB with its three fully owned subsidiaries and three international sales
companies are all active in the field of radiation therapy. An Extra
Shareholder Meeting took place Wednesday October 30th 2013.
Press release 2013-10-31
C-RAD AB with its three fully owned subsidiaries and three international sales companies are all active in the field of radiation therapy. An Extra Shareholder Meeting took place Wednesday October 30th 2013.
The shareholder meeting has resolved to amend the conditions for the convertible loans with a total amount of 9 064 450 SEK which Stiftelsen Norrlandsfonden is holding in C-RAD. The time within which the conversion may be requested has been extended to 31.1.2016. At the same time the due date has been changed to 28.2.2016. All other terms and conditions remain the same. Stifelsen Norrlandsfonden has agreed to the changes of condition and the revised terms. It is not expected to be detrimental to the company or its shareholders.
Frank Lohr has been elected as the new board member. Therewith the new board is constituted with Frank Lohr, Erik Hedlund, Bengt Lind and Peter Hamberg as board members. Börje Bengtsson will remain in position as Chairman of the Board.
C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 29 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has invested in 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier.
For more information on C-RAD, please visit www.c-rad.com.
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666931, E-mail firstname.lastname@example.org